Antidepressant effects of ketamine on depression-like behavior in juvenile mice after neonatal dexamethasone exposure

Clinical Psychopharmacology and Neuroscience

Volumn 12, Issue 2, 2014, Pages 124-127

  Li, Su Xia ^a,b   Zhang, Ji Chun ^a   Wu, Jin ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b PEKING UNIVERSITY   (China)

Author keywords

Antidepressants; Depression; Dexamethasone; Ketamine; NMDA receptors

Indexed keywords

DEXAMETHASONE; KETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FEMALE; FORCED SWIM TEST; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST;

EID: 84940328514     PISSN: 17381088     EISSN: 20934327     Source Type: Journal    
DOI: 10.9758/cpn.2014.12.2.124     Document Type: Article

References (24)

1. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 2002;59:225-231.
2. Cheung AH, Kozloff N, Sacks D. Pediatric depression: an evidence-based update on treatment interventions. Curr Psychiatry Rep 2013;15:381.
3. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
4. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
5. Li SX, Fujita Y, Zhang JC, Ren Q, Ishima T, Wu J, et al. Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure. Neurobiol Dis 2014;62:124-134.
6. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-997.
7. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563-569.
8. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-1316.
9. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105-123.
10. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1558-1568.
11. Hashimoto K. Therapeutic implications for NMDA receptors in mood disorders. Expert Rev Neurother 2013;13:735-737.
12. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010;18:293-303.
13. Tokita K, Yamaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 2012;100:688-704.
14. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354.
15. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
16. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
17. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72:537-547.
18. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-684.
19. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62:35-41.
20. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry 2013;18:1236-1241.
21. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002;52:503-528.
22. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
23. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.
24. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013;8:e56053.